康缘药业(600557.SH)：部分董事、高级管理人员拟合计不低于12万股股份

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) announced that several key executives plan to increase their holdings in the company, reflecting their confidence in its future development and long-term investment value [1] Group 1: Executive Shareholding Plan - The executives, including the general manager and several vice presidents, intend to purchase a total of no less than 120,000 shares within one month from the announcement date [1] - The shares to be purchased are part of the restricted stock incentive plan granted in 2022 [1] - The share purchase will not have a set price range and will be executed based on the stock price fluctuations and overall market trends [1]